This article is more than 5 years old. Information may no longer be current.

Xeomin approved as first-line blepharospasm treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has approved a supplemental biologics license application for Xeomin as a first-line treatment for blepharospasm, according to a press release from Merz.

Xeomin (incobotulinumtoxinA) was first approved to treat blepharospasm in 2010.

A randomized, double-blind, placebo-controlled, phase 3 clinical trial of 61 patients showed treated subjects had a –1.2 improvement in blepharospasm severity subscore as measured on the Jankovic rating scale compared to placebo-treated subjects (P = .004).

“Merz is proud to offer a first-line treatment option for blepharospasm, a devastating condition that has no cure and affects up to 50,000 patients in the U.S.,” Kevin O’Brien, vice president and U.S. head of neurosciences, Merz, said. “This milestone, along with the July 2018 approval of Xeomin for the treatment of chronic sialorrhea (drooling) in adults, reinforces our commitment to providing comprehensive care for patients living with movement disorders.”